Ayurvedic-Life International, LLC announced today that it's sponsored research at King's College-London featuring it's multi-patented next-generation Gymnema sylvestre extract, "validates its development for clinical use" per a research paper published in Cellular Physiology and Biochemistry, February 2009;23:125-132.

Low concentrations of the novel Gymnema sylvestre isolate stimulate insulin secretion in-vitro without compromising pancreatic beta cell viability, unlike the commonly used GS-4 standardized Gymnema sylvestre extract. Ayurvedic-Life's novel Gymnema sylvestre isolate has the ability to stimulate insulin secretion similar to sulphonylureas and meglitinide analogues that are currently used for the treatment of Type 2 Diabetes.

Ayurvedic-Life's novel Gymnema sylvestre isolate is produced from their patented proprietary extraction process that preserves the labile compounds of the key Active Principles of botanically pure Gymnema sylvestre leaves. Gymnema sylvestre is a unique plant that grows primarily in the Indian sub-continent and has been used as a natural folk medicine for maintaining optimal health since 6,000 B.C. Several tribes, including the Santals in east-central India have used Gymnema sylvestre leaves for centuries as a folk remedy.

Dr. Arun K. Chatterji, PhD, the inventor of the patented Gymnema sylvestre Virgin Isolate extraction technology and the Chairman and CEO of Ayurvedic-Life International, states, "My invention of the Ayurvedic Virgin Isolate technology coupled with the superb cellular level research performed at King's College-London has the potential to bring a truly unique health solution to millions of people worldwide.